Description:

Introduction to Bortezomib:

Bortezomib is a medication classified as a proteasome inhibitor. 

It is used in the treatment of certain types of cancers, particularly multiple myeloma and mantle cell lymphoma. 

Bortezomib works by interfering with the normal breakdown of proteins within cancer cells, leading to cell death.Uses of Bortezomib:

Multiple Myeloma: 

Bortezomib is a key component in the treatment of multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. 

It is often used in combination with other medications as part of initial therapy or for relapsed or refractory disease.

Mantle Cell Lymphoma: 

Bortezomib is also approved for the treatment of mantle cell lymphoma, a type of non-Hodgkin lymphoma. 

It is used in both newly diagnosed and relapsed/refractory cases of mantle cell lymphoma.

Mechanism of Action: 

Bortezomib exerts its anti-cancer effects by inhibiting the proteasome, a cellular complex responsible for degrading proteins. 

By disrupting this process, Bortezomib causes the accumulation of proteins within cancer cells, leading to cell stress and ultimately cell death.

Combination Therapy: 

Bortezomib is often used in combination with other chemotherapy drugs or targeted therapies to enhance its effectiveness in treating multiple myeloma and mantle cell lymphoma. 

These combinations are tailored to the individual patient's condition and may vary based on factors such as disease stage and response to treatment.

Administration: 

Bortezomib is typically administered by injection into a vein (intravenously) or under the skin (subcutaneously). 

The dosing schedule and frequency may vary depending on the specific treatment regimen prescribed by the healthcare provider.

Side Effects: 

Common side effects of Bortezomib may include nausea, diarrhea, fatigue, peripheral neuropathy, and low blood cell counts. 

Close monitoring and management of side effects are important during treatment with Bortezomib.

Bortezomib plays a crucial role in the treatment of multiple myeloma and mantle cell lymphoma, offering patients a targeted therapy option that can help control the progression of these cancers and improve outcomes.

Product Forms: Injectable Solution, Oral Capsules/Tablets

Payment method: T/T in advance, Paypal, Western Union, L/C, etc.

Shipping ways: Courier, Air, Sea, Road

Storage Condition: Dry, dark, and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).